Pooled analysis of two phase 3 RCTs and their open-label extension in moderate to severe hidradenitis suppurativa (556 patients entered): bimekizumab adverse event rates did not rise in Year 2 (235.7 vs 261.6/100 PY); 85.4% achieved HiSCR50 at Year 2.
Secondary analysisn = 556
Sayed et al. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension